Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy

Dennis J. Matthews, Katherine A. James, Lisa A. Miller, Shree Pandya, Kimberly A. Campbell, Emma Ciafaloni, Katherine D. Mathews, Timothy M. Miller, Christopher M Cunniff, F. John Meaney, Charlotte M. Druschel, Paul A. Romitti, Deborah J. Fox

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The use of corticosteroids for treatment of Duchenne and Becker muscular dystrophy in clinical practice from 1991 through 2005 was reviewed in a large population-based cohort (MD STARnet) of boys in 4 regional sites and 6 clinics of the United States. Corticosteroid use increased from 20% (11 of 56 individuals) in 1991 to 44% (93 of 218 individuals) in 2005. Average use varied by site and ranged from 15% to 49%. The median age of corticosteroid initiation was 6.9 years (range, 3.7-17.4 years). Dosage and growth information was available for 102 participants and showed a median dose as 0.729 mg/kg for prednisone and 0.831 mg/kg for deflazacort. T. The most common reasons that corticosteroids were discontinued included weight gain, behavioral side effects, and loss of ambulation, resulting in full-time wheelchair use. Substantial variations in clinical practice were identified among study sites.

Original languageEnglish (US)
Pages (from-to)1319-1324
Number of pages6
JournalJournal of Child Neurology
Volume25
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Duchenne Muscular Dystrophy
Adrenal Cortex Hormones
Population
Wheelchairs
Prednisone
Weight Gain
Walking
Growth
Therapeutics

Keywords

  • Becker muscular dystrophy
  • corticosteroids
  • Duchenne muscular dystrophy
  • population-based studies

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

Matthews, D. J., James, K. A., Miller, L. A., Pandya, S., Campbell, K. A., Ciafaloni, E., ... Fox, D. J. (2010). Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy. Journal of Child Neurology, 25(11), 1319-1324. https://doi.org/10.1177/0883073810362762

Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy. / Matthews, Dennis J.; James, Katherine A.; Miller, Lisa A.; Pandya, Shree; Campbell, Kimberly A.; Ciafaloni, Emma; Mathews, Katherine D.; Miller, Timothy M.; Cunniff, Christopher M; Meaney, F. John; Druschel, Charlotte M.; Romitti, Paul A.; Fox, Deborah J.

In: Journal of Child Neurology, Vol. 25, No. 11, 11.2010, p. 1319-1324.

Research output: Contribution to journalArticle

Matthews, DJ, James, KA, Miller, LA, Pandya, S, Campbell, KA, Ciafaloni, E, Mathews, KD, Miller, TM, Cunniff, CM, Meaney, FJ, Druschel, CM, Romitti, PA & Fox, DJ 2010, 'Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy', Journal of Child Neurology, vol. 25, no. 11, pp. 1319-1324. https://doi.org/10.1177/0883073810362762
Matthews, Dennis J. ; James, Katherine A. ; Miller, Lisa A. ; Pandya, Shree ; Campbell, Kimberly A. ; Ciafaloni, Emma ; Mathews, Katherine D. ; Miller, Timothy M. ; Cunniff, Christopher M ; Meaney, F. John ; Druschel, Charlotte M. ; Romitti, Paul A. ; Fox, Deborah J. / Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy. In: Journal of Child Neurology. 2010 ; Vol. 25, No. 11. pp. 1319-1324.
@article{5ed89d18ae6a46c3a2eae8585ba1af6d,
title = "Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy",
abstract = "The use of corticosteroids for treatment of Duchenne and Becker muscular dystrophy in clinical practice from 1991 through 2005 was reviewed in a large population-based cohort (MD STARnet) of boys in 4 regional sites and 6 clinics of the United States. Corticosteroid use increased from 20{\%} (11 of 56 individuals) in 1991 to 44{\%} (93 of 218 individuals) in 2005. Average use varied by site and ranged from 15{\%} to 49{\%}. The median age of corticosteroid initiation was 6.9 years (range, 3.7-17.4 years). Dosage and growth information was available for 102 participants and showed a median dose as 0.729 mg/kg for prednisone and 0.831 mg/kg for deflazacort. T. The most common reasons that corticosteroids were discontinued included weight gain, behavioral side effects, and loss of ambulation, resulting in full-time wheelchair use. Substantial variations in clinical practice were identified among study sites.",
keywords = "Becker muscular dystrophy, corticosteroids, Duchenne muscular dystrophy, population-based studies",
author = "Matthews, {Dennis J.} and James, {Katherine A.} and Miller, {Lisa A.} and Shree Pandya and Campbell, {Kimberly A.} and Emma Ciafaloni and Mathews, {Katherine D.} and Miller, {Timothy M.} and Cunniff, {Christopher M} and Meaney, {F. John} and Druschel, {Charlotte M.} and Romitti, {Paul A.} and Fox, {Deborah J.}",
year = "2010",
month = "11",
doi = "10.1177/0883073810362762",
language = "English (US)",
volume = "25",
pages = "1319--1324",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "11",

}

TY - JOUR

T1 - Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy

AU - Matthews, Dennis J.

AU - James, Katherine A.

AU - Miller, Lisa A.

AU - Pandya, Shree

AU - Campbell, Kimberly A.

AU - Ciafaloni, Emma

AU - Mathews, Katherine D.

AU - Miller, Timothy M.

AU - Cunniff, Christopher M

AU - Meaney, F. John

AU - Druschel, Charlotte M.

AU - Romitti, Paul A.

AU - Fox, Deborah J.

PY - 2010/11

Y1 - 2010/11

N2 - The use of corticosteroids for treatment of Duchenne and Becker muscular dystrophy in clinical practice from 1991 through 2005 was reviewed in a large population-based cohort (MD STARnet) of boys in 4 regional sites and 6 clinics of the United States. Corticosteroid use increased from 20% (11 of 56 individuals) in 1991 to 44% (93 of 218 individuals) in 2005. Average use varied by site and ranged from 15% to 49%. The median age of corticosteroid initiation was 6.9 years (range, 3.7-17.4 years). Dosage and growth information was available for 102 participants and showed a median dose as 0.729 mg/kg for prednisone and 0.831 mg/kg for deflazacort. T. The most common reasons that corticosteroids were discontinued included weight gain, behavioral side effects, and loss of ambulation, resulting in full-time wheelchair use. Substantial variations in clinical practice were identified among study sites.

AB - The use of corticosteroids for treatment of Duchenne and Becker muscular dystrophy in clinical practice from 1991 through 2005 was reviewed in a large population-based cohort (MD STARnet) of boys in 4 regional sites and 6 clinics of the United States. Corticosteroid use increased from 20% (11 of 56 individuals) in 1991 to 44% (93 of 218 individuals) in 2005. Average use varied by site and ranged from 15% to 49%. The median age of corticosteroid initiation was 6.9 years (range, 3.7-17.4 years). Dosage and growth information was available for 102 participants and showed a median dose as 0.729 mg/kg for prednisone and 0.831 mg/kg for deflazacort. T. The most common reasons that corticosteroids were discontinued included weight gain, behavioral side effects, and loss of ambulation, resulting in full-time wheelchair use. Substantial variations in clinical practice were identified among study sites.

KW - Becker muscular dystrophy

KW - corticosteroids

KW - Duchenne muscular dystrophy

KW - population-based studies

UR - http://www.scopus.com/inward/record.url?scp=78650186613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650186613&partnerID=8YFLogxK

U2 - 10.1177/0883073810362762

DO - 10.1177/0883073810362762

M3 - Article

C2 - 20207610

AN - SCOPUS:78650186613

VL - 25

SP - 1319

EP - 1324

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 11

ER -